CLINICAL TRIALS PROFILE FOR MECAMYLAMINE HYDROCHLORIDE

All Clinical Trials for MECAMYLAMINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00006399 ↗	Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease	Completed	Alzheimer's Association	Phase 2	1999-09-01	The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.
NCT00006399 ↗	Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease	Completed	Eisai Inc.	Phase 2	1999-09-01	The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.
NCT00006399 ↗	Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease	Completed	Pfizer	Phase 2	1999-09-01	The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.
NCT00006399 ↗	Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease	Completed	National Center for Research Resources (NCRR)	Phase 2	1999-09-01	The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.
NCT00018161 ↗	Treatment to Quit Smoking	Completed	US Department of Veterans Affairs	Phase 2	1997-01-01	This protocol evaluates the efficacy of combining pharmacologic treatments for smoking cessation, entailing the use of the nicotine skin patch with the nicotinic antagonist mecamylamine, with a specific behavioral therapy designed to inhibit the smoking urge.
NCT00018161 ↗	Treatment to Quit Smoking	Completed	VA Office of Research and Development	Phase 2	1997-01-01	This protocol evaluates the efficacy of combining pharmacologic treatments for smoking cessation, entailing the use of the nicotine skin patch with the nicotinic antagonist mecamylamine, with a specific behavioral therapy designed to inhibit the smoking urge.
NCT00018187 ↗	Combinations of Pharmacologic Smoking Cessation Treatments	Completed	US Department of Veterans Affairs	Phase 1	1998-11-01	The purpose of this study is to test the effectiveness of a combination of the drugs bupropion and mecamylamine along with a nicotine patch as a therapy for smoking cessation.

Clinical Trial Conditions for MECAMYLAMINE HYDROCHLORIDE

Condition Name

Condition Name for MECAMYLAMINE HYDROCHLORIDE
Intervention	Trials
Major Depressive Disorder	9
Depression	6
Smoking	2
Subjective Cognitive Decline	2

Condition MeSH

Condition MeSH for MECAMYLAMINE HYDROCHLORIDE
Intervention	Trials
Depressive Disorder	11
Depression	10
Depressive Disorder, Major	10
Disease	9

Clinical Trial Locations for MECAMYLAMINE HYDROCHLORIDE

Trials by Country

Trials by Country for MECAMYLAMINE HYDROCHLORIDE
Location	Trials
United States	117
India	42
Japan	11
Colombia	4
Germany	4

Trials by US State

Trials by US State for MECAMYLAMINE HYDROCHLORIDE
Location	Trials
Ohio	7
Connecticut	6
California	6
Kansas	6
Florida	6

Clinical Trial Progress for MECAMYLAMINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for MECAMYLAMINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	7
Phase 2	10

Clinical Trial Status

Clinical Trial Status for MECAMYLAMINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	24
Not yet recruiting	2
Terminated	2

Clinical Trial Sponsors for MECAMYLAMINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for MECAMYLAMINE HYDROCHLORIDE
Sponsor	Trials
AstraZeneca	10
Targacept Inc.	7
Yale University	3

Sponsor Type

Sponsor Type for MECAMYLAMINE HYDROCHLORIDE
Sponsor	Trials
Industry	23
Other	22
NIH	4